![Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1539706083576631296/9rqRL-CM_200x200.jpg)
![ilyas sahin, MD(@ilyassahinMD) 's Twitter Profile Photo ilyas sahin, MD(@ilyassahinMD) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1476296269236682766/2pIbMCqG_200x200.jpg)
![NaniAro 🇪🇸🇮🇨💚💚(@JMArocha1) 's Twitter Profile Photo NaniAro 🇪🇸🇮🇨💚💚(@JMArocha1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1613633497842782226/KbQ6F87q_200x200.jpg)
![DEÜ. Onkoloji Enstitüsü Müdürlüğü(@deuonkoloji) 's Twitter Profile Photo DEÜ. Onkoloji Enstitüsü Müdürlüğü(@deuonkoloji) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1185142054269181952/DKBpww9X_200x200.jpg)
7 Kasım 2023 Salı günü saat 12.30 'da Ali Furkan KIDIL'ın ' HER2-Selective and Reversible Tyrosine Kinase updates Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer ' sunumuna katılımlarınızı bekliyoruz.
#universitemdeu
![DEÜ. Onkoloji Enstitüsü Müdürlüğü (@deuonkoloji) on Twitter photo 2023-11-06 08:03:32 7 Kasım 2023 Salı günü saat 12.30 'da Ali Furkan KIDIL'ın ' HER2-Selective and Reversible Tyrosine Kinase updates Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer ' sunumuna katılımlarınızı bekliyoruz.
#universitemdeu 7 Kasım 2023 Salı günü saat 12.30 'da Ali Furkan KIDIL'ın ' HER2-Selective and Reversible Tyrosine Kinase updates Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer ' sunumuna katılımlarınızı bekliyoruz.
#universitemdeu](https://pbs.twimg.com/media/F-PG36gXwAEtFSv.jpg)
![Soraia Lobo-Martins(@S_LoboMartins) 's Twitter Profile Photo Soraia Lobo-Martins(@S_LoboMartins) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1316037159967744005/JCj7P2sh_200x200.jpg)
![Dr Sarah Sammons(@drsarahsam) 's Twitter Profile Photo Dr Sarah Sammons(@drsarahsam) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1347613395248443399/WnKp8SCZ_200x200.jpg)
![Yakup Ergün(@dr_yakupergun) 's Twitter Profile Photo Yakup Ergün(@dr_yakupergun) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1611316237493043200/inI6_vGk_200x200.jpg)
Tucatinib and Trastuzumab for Previously Treated HER2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
🔍30 patients
ORR➡️46.7%
mPFS➡️5.5 mo
1y OS➡️53.6%
Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
![Yakup Ergün (@dr_yakupergun) on Twitter photo 2023-09-26 20:39:16 Tucatinib and Trastuzumab for Previously Treated HER2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
🔍30 patients
ORR➡️46.7%
mPFS➡️5.5 mo
1y OS➡️53.6%
@JCO_ASCO ascopubs.org/doi/10.1200/JC… Tucatinib and Trastuzumab for Previously Treated HER2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
🔍30 patients
ORR➡️46.7%
mPFS➡️5.5 mo
1y OS➡️53.6%
@JCO_ASCO ascopubs.org/doi/10.1200/JC…](https://pbs.twimg.com/media/F6-qqawW4AA8I4A.jpg)
![Dr. Iván R. González(@Dr_Ivanoncologo) 's Twitter Profile Photo Dr. Iván R. González(@Dr_Ivanoncologo) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1579544553966665748/th6KMh7c_200x200.jpg)
![Pablo Cambronero 🇪🇦(@PabloCamPiq) 's Twitter Profile Photo Pablo Cambronero 🇪🇦(@PabloCamPiq) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1646193253715263493/7gxYp8Su_200x200.jpg)
![Noelle LoConte, MD, FASCO(@loconte) 's Twitter Profile Photo Noelle LoConte, MD, FASCO(@loconte) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1671986827715129345/JRQ8TxHF_200x200.jpg)
![Wungki Park, MD MS(@CentralParkWMD) 's Twitter Profile Photo Wungki Park, MD MS(@CentralParkWMD) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1599999070373912577/H5wjRnKq_200x200.jpg)
Great 🚨 news for patients with #HER2 (+) #ERBB2 amp BTC #BiliaryTractCancer Novel Tx options #tucatinib #trastuzumab #zanidatamab #ASCO23 congrats 🎉🎊 for the authors!
![Wungki Park, MD MS (@CentralParkWMD) on Twitter photo 2023-06-02 22:22:45 Great 🚨 news for patients with #HER2 (+) #ERBB2 amp BTC #BiliaryTractCancer Novel Tx options #tucatinib #trastuzumab #zanidatamab #ASCO23 congrats 🎉🎊 for the authors! Great 🚨 news for patients with #HER2 (+) #ERBB2 amp BTC #BiliaryTractCancer Novel Tx options #tucatinib #trastuzumab #zanidatamab #ASCO23 congrats 🎉🎊 for the authors!](https://pbs.twimg.com/media/Fxpp7NMXwAE8SRf.jpg)
![Suneel Kamath MD(@SKamath_MD) 's Twitter Profile Photo Suneel Kamath MD(@SKamath_MD) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1729503917728215040/9GsNQU3c_200x200.jpg)
![Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1539706083576631296/9rqRL-CM_200x200.jpg)
Tucatinib & Trastuzumab for HER2 2+ Metastatic Biliary Tract Cancer
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
👉ORR 46.7%, mPFS 5.5 mo, mOS 15.5mo
👉very intersting data, more & more options for Her2+ BTC ->best strategy? 💊sequencing? Resistance mechanism?
ESMO - Eur. Oncology EASL Education ILCA…
![Arndt Vogel (@ArndtVogel) on Twitter photo 2023-09-27 18:03:52 Tucatinib & Trastuzumab for HER2 2+ Metastatic Biliary Tract Cancer
@JCO_ASCO
doi.org/10.1200/JCO.23…
👉ORR 46.7%, mPFS 5.5 mo, mOS 15.5mo
👉very intersting data, more & more options for Her2+ BTC ->best strategy? 💊sequencing? Resistance mechanism?
@myESMO @EASLedu @ILCAnews… Tucatinib & Trastuzumab for HER2 2+ Metastatic Biliary Tract Cancer
@JCO_ASCO
doi.org/10.1200/JCO.23…
👉ORR 46.7%, mPFS 5.5 mo, mOS 15.5mo
👉very intersting data, more & more options for Her2+ BTC ->best strategy? 💊sequencing? Resistance mechanism?
@myESMO @EASLedu @ILCAnews…](https://pbs.twimg.com/media/F7DQcoxXIAAD2sZ.jpg)
![Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo Arndt Vogel(@ArndtVogel) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1539706083576631296/9rqRL-CM_200x200.jpg)
Tucatinib & Trastuzumab for Previously Treated HER 2–Positive Metastatic Biliary Tract Cancer
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
🔎SGNTUC-019, 30pts
👉ORR 46.7%, DCR 76.7%, PFS 5.5 mo, mOS 15.5 mo
🧐Consistent efficacy of HER2🎯💊in BTC
ESMO - Eur. Oncology EASLnews ILCA Cholangiocarcinoma Foundation…
![Arndt Vogel (@ArndtVogel) on Twitter photo 2023-12-17 10:05:50 Tucatinib & Trastuzumab for Previously Treated HER 2–Positive Metastatic Biliary Tract Cancer
@JCO_ASCO
doi.org/10.1200/JCO.23…
🔎SGNTUC-019, 30pts
👉ORR 46.7%, DCR 76.7%, PFS 5.5 mo, mOS 15.5 mo
🧐Consistent efficacy of HER2🎯💊in BTC
@myESMO @EASLnews @ILCAnews @curecc… Tucatinib & Trastuzumab for Previously Treated HER 2–Positive Metastatic Biliary Tract Cancer
@JCO_ASCO
doi.org/10.1200/JCO.23…
🔎SGNTUC-019, 30pts
👉ORR 46.7%, DCR 76.7%, PFS 5.5 mo, mOS 15.5 mo
🧐Consistent efficacy of HER2🎯💊in BTC
@myESMO @EASLnews @ILCAnews @curecc…](https://pbs.twimg.com/media/GBir_v8XkAAspCW.jpg)
![Jun Gong(@jgong15) 's Twitter Profile Photo Jun Gong(@jgong15) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1633992619880759296/DvLw63oO_200x200.jpg)
![Santiesteban(@s_santiesteban) 's Twitter Profile Photo Santiesteban(@s_santiesteban) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1649380828026224640/oXT6WCmz_200x200.jpg)
![Mike Pishvaian(@MPishvaian) 's Twitter Profile Photo Mike Pishvaian(@MPishvaian) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1055283139646513152/EW1IBKsH_200x200.jpg)
Targeting Her2 amplified #chlolangiocarcinoma two different ways 👍
Dr. Yoshiaki Nakamura presented 30 patients treated with tucatinib and trasruzumab
👉46.7% ORR - wonderful‼️
![Mike Pishvaian (@MPishvaian) on Twitter photo 2023-06-02 22:38:53 Targeting Her2 amplified #chlolangiocarcinoma two different ways 👍
Dr. Yoshiaki Nakamura presented 30 patients treated with tucatinib and trasruzumab
👉46.7% ORR - wonderful‼️ Targeting Her2 amplified #chlolangiocarcinoma two different ways 👍
Dr. Yoshiaki Nakamura presented 30 patients treated with tucatinib and trasruzumab
👉46.7% ORR - wonderful‼️](https://pbs.twimg.com/media/Fxptnx5XgAcQKYm.jpg)
![Jenny Seligmann(@JenSeligmann) 's Twitter Profile Photo Jenny Seligmann(@JenSeligmann) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/699203885978796032/GKaruK0e_200x200.jpg)
10/14
What next...?
foxtrot-study Platform Yorkshire Cancer Research
OPEN IN UK
👍FOxTROT 2 - NAC in older pts
👍FOxTROT 3 - NAC with mFOLFOXIRI
COMING SOON
👍 FOxTROT 4 - Enco/Cetux in BRAF-mut pts
👍FOxTROT HER2 - Tucatinib/Tras in HER2 +ve pts
👍FOxTROT-IO - watch for news soon 😉
![Jenny Seligmann (@JenSeligmann) on Twitter photo 2023-01-20 01:48:21 10/14
What next...?
@FoxtrotStudy Platform @yorkshirecancer
OPEN IN UK
👍FOxTROT 2 - NAC in older pts
👍FOxTROT 3 - NAC with mFOLFOXIRI
COMING SOON
👍 FOxTROT 4 - Enco/Cetux in BRAF-mut pts
👍FOxTROT HER2 - Tucatinib/Tras in HER2 +ve pts
👍FOxTROT-IO - watch for news soon 😉 10/14
What next...?
@FoxtrotStudy Platform @yorkshirecancer
OPEN IN UK
👍FOxTROT 2 - NAC in older pts
👍FOxTROT 3 - NAC with mFOLFOXIRI
COMING SOON
👍 FOxTROT 4 - Enco/Cetux in BRAF-mut pts
👍FOxTROT HER2 - Tucatinib/Tras in HER2 +ve pts
👍FOxTROT-IO - watch for news soon 😉](https://pbs.twimg.com/media/Fm4MdEoagAAwEGJ.jpg)
![Sara Tolaney(@stolaney1) 's Twitter Profile Photo Sara Tolaney(@stolaney1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1446886234169790466/Ae54vzan_200x200.jpg)
![Dr Amol Akhade(@SuyogCancer) 's Twitter Profile Photo Dr Amol Akhade(@SuyogCancer) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1363281714022215680/4JxeUbEP_200x200.jpg)